Quintiles has added a comprehensive suite of biomarker assays to investigate the phosphoinositide 3-kinases (PI3K) cancer survival pathway, the focus of numerous anti-cancer therapies under development. Understanding the PI3K pathway is key to developing new drugs to inhibit or block this pathway, cutting off a metabolic function needed for certain cancers to survive, according to a company statement. “P13K is an important target for many biopharmaceutical companies,” said Sarah Bacus, Ph.D.,...